MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Bullish option flow detected in Eli Lilly (LLY) with 44,692 calls trading, 3x expected, and implied vol increasing over 1 point to 29.25%. 11/8 weekly 820 calls and 11/8 weekly 830 calls are the most ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other S&P 500 stocks. As per AXA Investment Managers, the US dominated financial markets this ...

Eli Lilly (NYSE ... Drug Administration (FDA) approved Lilly's new eczema treatment, Ebglyss. In the long-term ADjoin study, treatment with the monthly injection controlled eczema for up to ...

What would a Harris or Trump presidency mean for health care policy? Why did Eli Lilly’s Mounjaro and Zepbound sales miss expectations? And does Adam believe in ghosts? We talk about all that an ...

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE: LLY) has had a strong run this year, up more than 55%. However, the company's success goes back much further, with the ...

Those who follow my work closely know that I have been a big fan of pharmaceutical firm Eli Lilly and Company (NYSE:LLY) for a little while now. My first article about the company, published in ...

Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets with new data readouts. J&J evaluated its Tremfya in patients with low ...

Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion.

According to a New York Times report this week, Eisai and Eli Lilly, in the clinical trials for their respective Alzheimer’s drugs Leqembi and Kisunla, genetically tested participants to ...

At the end of August, Eli Lilly announced it would sell single-use vials of Zepbound directly to patients at a significantly lower price than its injection pens. Affordability is Galindo's top ...

A U.K. watchdog has declined to endorse Eli Lilly’s (NYSE ... have been eligible for treatment with donanemab. Donanemab, an injection for intravenous infusion every four weeks, is indicated ...